Vericel (VCEL) Long-Term Investments (2019 - 2026)
Vericel (VCEL) posted Long-Term Investments of $102.1 million for Q2 2026, up 0.79% sequentially from $101.3 million in Q1 2026, and up 21.98% YoY from $83.7 million in Q2 2025.
Analysis
Vericel (VCEL) Long-Term Investments (2019 - 2026) Analysis & Trends
Vericel has reported Long-Term Investments for 8 years, with the latest figure at $102.1 million in Q2 2026.
- Quarterly Long-Term Investments rose 21.98% year-over-year to $102.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $102.1 million (up 21.98% YoY) and the FY2025 annual result came in at $61.4 million, up 53.95% from the prior year.
- Long-Term Investments improved to $102.1 million in Q2 2026 per VCEL's latest filing, from $101.3 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $102.1 million in Q2 2026 and troughed at $20.0 million in Q4 2022.
- A 5-year average of $70.0 million and a median of $76.4 million in 2023 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2022 and 2024: Long-Term Investments retreated 22.29% in 2022, then surged 57.73% in 2024.
- Over 5 years, Long-Term Investments stood at $20.0 million in 2022, then gained by 26.66% to $25.3 million in 2023, then soared by 57.73% to $39.9 million in 2024, then soared by 53.95% to $61.4 million in 2025, then surged by 66.3% to $102.1 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $102.1 million, $101.3 million, and $61.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 102.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 102.10 Mn |
| Mar 31, 2026 | 101.30 Mn |
| Dec 31, 2025 | 61.40 Mn |
| Sep 30, 2025 | 84.60 Mn |
| Jun 30, 2025 | 83.70 Mn |
| Mar 31, 2025 | 82.80 Mn |
| Dec 31, 2024 | 39.88 Mn |
| Sep 30, 2024 | 80.90 Mn |
| Jun 30, 2024 | 78.30 Mn |
| Mar 31, 2024 | 77.10 Mn |
| Dec 31, 2023 | 25.28 Mn |
| Sep 30, 2023 | 65.10 Mn |
| Jun 30, 2023 | 75.80 Mn |
| Mar 31, 2023 | 77.40 Mn |
| Dec 31, 2022 | 19.96 Mn |
| Sep 30, 2022 | 67.50 Mn |
| Jun 30, 2022 | 68.40 Mn |
| Mar 31, 2022 | 67.70 Mn |
| Dec 31, 2021 | 25.69 Mn |
| Sep 30, 2021 | 64.00 Mn |